Ipv Mérieux (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

Ipv Mérieux, an inactivated poliovirus vaccine, is used in the immunization pathway to prevent poliomyelitis.

• Poliomyelitis: provides active immunity against poliovirus types 1, 2, and 3.
• Childhood immunization schedule: contributes to routine vaccination programs for infants and toddlers.
• Travel vaccination: protects travelers to regions where poliovirus transmission persists.
• Outbreak control: employed in mass vaccination campaigns during poliovirus outbreaks.

• The vaccine contains chemically inactivated poliovirus strains (types 1, 2, and 3). After intramuscular or subcutaneous injection, the viral antigens are taken up by antigen‑presenting cells, stimulating B‑cell production of neutralising antibodies and priming T‑cell responses, thereby establishing active, long‑lasting immunity against poliovirus infection.

Common adverse reactions are generally mild and self‑limiting.

Common Side Effects

• Pain at injection site: local discomfort after administration.
• Redness or swelling: mild inflammation around the injection area.
• Fever: transient low‑grade temperature rise.
• Irritability or fussiness: especially in young children.
• Headache: occasional mild headache post‑vaccination.
• Fatigue: temporary tiredness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Aseptic meningitis: rare inflammation of the meninges not caused by bacteria.
• Guillain‑Barré syndrome: extremely rare autoimmune neuropathy.
• Seizures: infrequent neurologic events.
• Severe hypotension: sudden drop in blood pressure.
• Extensive local reaction: large area of swelling or necrosis.

Vaccination should be administered after careful assessment of individual health status.

• Contraindication: severe allergy to any vaccine component.
• Immunocompromised patients: evaluate risk‑benefit before use.
• Pregnancy: limited safety data; vaccinate only if benefit outweighs risk.
• Breastfeeding: generally considered compatible, but monitor infant.
• Age restrictions: not recommended for infants younger than 6 weeks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other immunizations or immune‑modulating agents.

Major Interactions (Avoid)

• Live attenuated vaccines: avoid co‑administration within 4 weeks.
• Immunoglobulin therapy: postpone vaccination for at least 4 weeks after receipt.
• Blood products: defer vaccination for 4 weeks following transfusion.

Moderate Interactions (Monitor Closely)

• Immunosuppressive drugs: may reduce vaccine efficacy; monitor antibody response.
• Systemic corticosteroids: assess timing and dosage to ensure adequate immunity.
• Chronic illnesses (e.g., HIV, diabetes): may alter immune response; observe closely.